Pilot Study of FFP104 Dose Escalation in PBC Subjects
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the initial safety, tolerability and
pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC